Sarepta price target lowered to $34 from $52 at Roth Capital
Roth Capital lowered its price target for Sarepta shares to $34 saying the company's 144-week data from the eteplirsen phase 2b study failed to meet high expectations. Roth believes the overall data remains "robust” with an 8.5% decline in walking ability in boys who on average are 12 years old. The firm thinks accelerated approval remains likely during the second half of 2015 and it keeps a Buy rating on the stock.
Terms and Privacy Policy